In July 2024 Imugene gave an excellent investor presentation which provided a snapshot of their current trials and also provided a corporate plan of possible scenarios to progress their products, i.e. licensing, partnering, selling products, or selling the company.
In my opinion I don't believe that they any longer wish to sell the Company and that they will prefer any of the other options so that they continue to see the development of their products as well as having a say in how they further develop. (This is of course barring a hostile takeover which could happen, but is unlikely given the control availble to top shareholders).
Imugene will now be very aware of the progress of the trials without doing a data cut and while there may still be some time to go before FDA approval we will very soon have a lot of interest in the OnCARlytics program amongst several companies who have approved CD-19 targeting agents.
As well as this we may also see interest coming from countries where we recently obtained patents.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)